Astrocyte Pharmaceuticals Secures Series B Funding
Astrocyte Pharmaceuticals, a company focused on developing neuroprotective drugs, has successfully raised $9.5 million in a Series B funding round. The funding, completed on September 30, 2026, was led by DeepWork Capital. Other participants in the round included MintPharma Capital, Waterstar Capital, Dynagrow Capital, and Angel Star Ventures.
Leadership and Vision
William Korinek, CEO and Co-Founder of Astrocyte Pharmaceuticals, plays a pivotal role in steering the company's innovative approach to drug development. Although specific quotes from Korinek were not available, his leadership is integral to the company's strategy and execution.
Strategic Use of Funds
The newly secured funds are expected to be directed towards advancing the development of Astrocyte Pharmaceuticals' neuroprotective drug pipeline. This will likely include further research and development, clinical trials, and possibly expanding the team to support these initiatives.
About the Investors
DeepWork Capital, the lead investor in this round, is known for its focus on life sciences and technology investments. The participation of other investors such as MintPharma Capital, Waterstar Capital, Dynagrow Capital, and Angel Star Ventures underscores the growing interest in Astrocyte Pharmaceuticals’ potential to make significant advancements in neuroprotection.
Location
Astrocyte Pharmaceuticals is based in Groton, Connecticut, United States.